TCF7L2 and familial pancreatic carcinoma: We anticipate that future studies employing isoform-specific antibodies to identify TCF7L2 binding sites in normal and diseased tissues will provide additional insight into the transcriptional networks that are altered in diseases such as type 2 diabetes, pancreatic cancer, and coronary artery disease.